Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Guardant Health, Inc.

< Previous 1 2 3 4 5 6 Next >
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in the 2021 Stifel Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports Third Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Appoints Myrtle Potter to Its Board of Directors
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports Second Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
From Guardant Health, Inc.
Via Business Wire
Tickers GH
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
From Guardant Health, Inc.
Via Business Wire
Tickers GH
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.